Alley EW ML

Glen Reid

Glover AR

Himanshu Brahmbhatt

Jennifer MacDiarmid

Michael Boyer

Nick Pavlakis

Nico van Zandwijk

Reid GWM

Stephen Clarke

Steven C Kao

Ueno T

 miRNAs are responsible for post-transcriptional control of gene expression, and are frequently downregulated in cancer. It has become well established that restoring miRNA levels can inhibit tumor growth, and many studies have demonstrated this in preclinical models. This in turn has led to the first clinical trials of miRNA replacement therapy. This special report focuses on the development of TargomiRs – miRNA mimics delivered by targeted bacterial minicells – and the very first clinical experience of a miRNA replacement therapy in thoracic cancer patients in the Phase I MesomiR-1 trial. </jats:p

Crossref

Epigenomics

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

Abstract

Similar works

Full text

Available Versions

Crossref